Sales of 5 C-RAD Sentinel and Catalyst systems sold radiation therapy clinics in the US
C-RAD AB with its three fully owned subsidiaries and three international sales companies are all active in the field of radiation therapy. After the decline of the US market in 2012 a recovery can be seen. C-RAD has during last months sold five Sentinel and Catalyst systems to clinics in the US.
The Catalyst system is based on a new generation hardware and software platform for high performance optical surface scanning and augmented reality through re-projection. Advanced and highly optimized algorithms for non-rigid registration and deformable models enable real-time assessment of patient positioning errors before and during treatment delivery. The system calculates isocenter adjustments and interfaces to major vendors ensure a completely integrated workflow. The C-RAD Sentinel system, based on laser technology, is offering advanced functionality for 4DCT.
In May 2012 the US administration announced the intention to reduce the reimbursement for radiation therapy treatments with 20%. 1 November 2012 a modest reduction of 9 % in Medicare was decided. During the period of uncertainty projects at the clinics were postponed or even cancelled. The result was a decline in sales of new equipment. Due to the financial turbulences investments in radiation therapy will continue to fluctuate.
Erik Hedlund, CEO, C-RAD AB:
“For C-RAD as for the vendors working radiation therapy last year sales in the US were below expectations. With the five new orders a recovery can be seen. With interfaces to main vendors in diagnostics and radiation therapy as well as increased capacity in direct sales a further growth is expected.”
About C-RAD
C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 24 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company’s first product, the C-RAD SentinelTM, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has acquired 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier.
For more information on C-RAD, please visit www.c-rad.com.
For further information:
Erik Hedlund, CEO C-RAD AB, Phone +46-18-666931, E-mail erik.hedlund@c-rad.se